Medicine and Dentistry
Malignant Neoplasm
100%
Emergency Department
89%
Immune Checkpoint Inhibitor
35%
Infection
32%
Procalcitonin
32%
Neutropenia
24%
COVID-19
23%
Intensive Care Unit
19%
Immunity
19%
Triage
17%
Central Venous Catheter
17%
Febrile Neutropenia
16%
Immune-Related Adverse Events
16%
Antimicrobial Therapy
15%
Treatment Duration
15%
Adverse Effect
15%
Venous Thromboembolism
14%
Antibiotics
13%
Advanced Cancer
12%
Lactic Acid
12%
Adverse Event
12%
Chimeric Antigen Receptor T-Cell
11%
Bloodstream Infection
11%
Cancer Therapy
11%
Hematologic Malignancy
11%
Catheter Removal
10%
Catheter Infection
10%
Diabetic Ketoacidosis
9%
Myocarditis
9%
Brain Metastasis
9%
Cohort Effect
9%
Supportive Care
9%
Hospital Mortality
9%
Pembrolizumab
8%
Oncology
8%
Recurrent Disease
7%
Chimeric Antigen Receptor T-Cell Immunotherapy
7%
Genome Wide Association Study
7%
Oxygen Saturation
7%
Infusion Therapy
7%
Blood Culture
7%
Neuropathic Pain
7%
Phlebothrombosis
7%
Head and Neck Cancer
7%
Advance Care Planning
7%
Ceftolozane
7%
Catheter Thrombosis
7%
End of Life Care
7%
Neuropathy
7%
Postcovid Syndrome
7%
Keyphrases
Cancer Patients
70%
In Cancer
42%
Emergency Department
40%
Comprehensive Cancer Center
31%
Patients with Cancer
31%
Procalcitonin
25%
Neutropenia
19%
Antimicrobial Therapy
17%
Emergency Department Observation Unit
15%
Documented Infection
15%
Duration of Therapy
15%
Hospital Mortality
15%
Bloodstream Infection
15%
Immune Checkpoint Inhibitors
15%
COVID-19
13%
Risk Factors
12%
Emergency Department Visits
11%
Chimeric Antigen Receptor T Cells (CAR-T)
10%
30-day Mortality
10%
Presenting Symptoms
9%
Pembrolizumab
9%
Poor Outcome
9%
Patients with Advanced Cancer
9%
Intensive Care Unit Admission
9%
Docetaxel Chemotherapy
7%
Chimeric Antigen Receptor T-cell Therapy
7%
Survivorship
7%
Cell Infusion
7%
In-hospital Mortality
7%
Treatment Modalities
7%
Immune-related Adverse Effects
7%
Adverse Events Profile
7%
Risk Treatment
7%
Anticancer Immune Response
7%
International multicenter Study
7%
Immune Checkpoint Therapy
7%
Checkpoint Inhibitor Immunotherapy
7%
MR-proADM
7%
Retrospective Cohort Study
7%
Central Venous Catheter
7%
Bupropion
7%
Gut Microbiome
7%
Emergency Severity Index
7%
Observation Medicine
7%
Sepsis Biomarkers
7%
Cancer Pain
7%
Smoking Abstinence
7%
Emergency Department Use
7%
Adverse Effects
7%
COVID-19 Inpatients
7%
Nursing and Health Professions
Emergency Ward
63%
Malignant Neoplasm
34%
Cancer Center
31%
Procalcitonin
23%
Advanced Cancer
19%
Hospital Mortality
18%
Intensive Care Unit
18%
Triage
17%
Central Venous Catheter
17%
Infection
17%
Observation Unit
15%
Treatment Duration
15%
Antimicrobial Therapy
15%
Neutropenia
15%
Confidence Interval
11%
Bloodstream Infection
11%
Delirium
11%
Palliative Therapy
11%
Dyspnea
10%
Catheter Removal
10%
Catheter Infection
10%
Length of Stay
8%
Myocarditis
7%
Recurrent Disease
7%
Tissue Oxygenation
7%
Febrile Neutropenia
7%
Blood Culture
7%
Advance Care Planning
7%
Syndrome
7%
Emergency Severity Index
7%
Myositis
7%
Vein Thrombosis
7%
Terminal Care
7%
Hemoptysis
7%
Catheter Thrombosis
7%
Cancer Pain
7%
Diseases
7%
Myasthenia gravis
7%
Systematic Review
7%
Mortality Rate
7%
Logistic Regression Analysis
6%
Venous Thromboembolism
6%
Anticoagulation
5%
